🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

23 recruiting trials

for KRAS-mutant Non-small Cell Lung Cancer (NSCLC)

A Study of Calderasib (MK-1084) Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004/KANDLELIT-004) NCT06345729Phase 3246 sites📍 Bakersfield📍 Beverly Hills📍 Stamford Merck Sharp & Dohme LLC · Tests: Calderasib, Placebo, Pembrolizumab Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer NCT06890598Phase 3366 sites📍 Huntsville📍 Mobile📍 Phoenix Eli Lilly and Company · Tests: Olomorasib, Pembrolizumab, Durvalumab, Placebo Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors NCT06040541Phase 117 sites📍 Sacramento📍 New Haven📍 Sarasota Revolution Medicines, Inc. · Tests: RMC-9805, RMC-6236 Phase 1/2a Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of WEF-001 as Monotherapy in Advanced KRAS-Mutant Solid Tumours. NCT07148128Phase 1, Phase 24 sites📍 Dallas📍 San Antonio📍 Toronto Auricula Biosciences Inc. · Tests: WEF-001 A Clinical Study of Calderasib (MK-1084) and Other Treatments for Participants With Non-Small Cell Lung Cancer (MK-1084-007/KANDLELIT-007) NCT07190248Phase 3221 sites📍 Birmingham📍 Farmington📍 Stamford Merck Sharp & Dohme LLC · Tests: Calderasib, Pembrolizumab (+) Berahyaluronidase alfa, Pemetrexed, Cisplatin, Carboplatin A Study to Learn About Study Medicine ALTA3263 in Adults With Advanced Solid Tumors With KRAS Mutations NCT06835569Phase 114 sites📍 Orlando📍 Tampa📍 Boston Alterome Therapeutics, Inc. · Tests: ALTA3263, cetuximab, mFOLFOX6, Pembrolizumab, Pemetrexed + Cisplatin /Carboplatin A First-in-Human Trial of BLU-924 (SAR449336) in Advanced Solid Tumors Harboring KRAS Mutations NCT07629960Phase 1, Phase 216 sites📍 Sarasota📍 Tampa📍 Baton Rouge Blueprint Medicines Corporation · Tests: BLU-924 KRAS-Targeted Vaccine With Chemoimmunotherapy, Nivolumab and Ipilimumab for Patients With NSCLC NCT05254184Phase 11 site📍 Baltimore Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins · Tests: Pooled Mutant KRAS-Targeted Long Peptide Vaccine 0.3mg each; 1.8mg total peptides A Clinical Trial of Calderasib (MK-1084) and Durvalumab in People With Non-Small Cell Lung Cancer (MK-1084-015/KANDLELIT-015) NCT07554339Phase 3103 sites📍 Savannah📍 Lisle📍 Lincoln Merck Sharp & Dohme LLC · Tests: Calderasib, Durvalumab, Placebo to MK-1084 Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors NCT07349537Phase 19 sites📍 New Haven📍 Baltimore📍 Boston Revolution Medicines, Inc. · Tests: RMC-5127, daraxonrasib, cetuximab Ladarixin With Sotorasib in Advanced NSCLC NCT05815173Phase 16 sites📍 Garden City📍 Mineola📍 New Hyde Park NYU Langone Health · Tests: Sotorasib, Ladarixin MK-3475A±Calderasib (MK-1084) in Completely Resected Stage IIA-IIIB (N2) KRAS G12Cm NSCLC (MK-1084-013) NCT07431827Phase 3117 sites📍 Ciudad Autónoma de Buenos Aires📍 Rosario📍 CABA Merck Sharp & Dohme LLC · Tests: Calderasib, MK-3475A, Placebo Open-label Study of BBO-8520 in Adult Subjects With KRASG12C Non-small Cell Lung Cancer NCT06343402Phase 138 sites📍 Birmingham📍 La Jolla📍 San Francisco TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics) · Tests: BBO-8520, Pembrolizumab, BBO-10203 T Cell Receptor T Cells for Advanced KRAS G12V-mutant Non-small Cell Lung Cancer, Pancreas Cancer, Colon Cancer NCT06043713Phase 11 site📍 Seattle Fred Hutchinson Cancer Center · Tests: Bendamustine, Biopsy, Biospecimen Collection, Computed Tomography, Cyclophosphamide A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer NCT06119581Phase 3416 sites📍 Huntsville📍 Gilbert📍 Phoenix Eli Lilly and Company · Tests: LY3537982, Pembrolizumab, Placebo, Cisplatin, Carboplatin TCR1188-ABC Cells in KRAS-mutated Cancers NCT07594067Phase 11 site📍 Philadelphia University of Pennsylvania · Tests: TCR1188-ABC cells, Fludarabine + Cyclophosphamide combination, Tocilizumab Fulzerasib Sequential Sintilimab Plus Platinum-Doublet Neoadjuvant Therapy for Resectable KRAS G12C-Mutant NSCLC NCT07492342Phase 23 sites📍 Beijing📍 Guangzhou📍 Zhejiang Jianxing He · Tests: fulzerasib A Phase 1 Dose Escalation and Dose Expansion Trial of KST-6051 in Participants With Advanced Solid Tumors With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Mutation NCT07458347Phase 19 sites📍 Los Angeles📍 Sarasota📍 Tampa Kestrel Therapeutics, Inc. · Tests: KST-6051, Gemcitabine/nab-paclitaxel, Cetuximab, Pembrolizumab, mFOLFOX6 A Study of Sotorasib in People With Non-Small Cell Lung Cancer NCT06582771Phase 27 sites📍 Basking Ridge📍 Middletown📍 Montvale Memorial Sloan Kettering Cancer Center · Tests: Sotorasib Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors NCT06128551Phase 1, Phase 256 sites📍 Duarte📍 Orange📍 Sacramento Revolution Medicines, Inc. · Tests: Elironrasib, Daraxonrasib Phase II Neoadjuvant Study of Garsorasib Followed by Ivonescimab Plus Chemotherapy in Resectable Stage IIA-IIIB KRAS G12C-Mutant NSCLC (GIVEN Study) NCT07472478Phase 21 site📍 Guangzhou Guangdong Provincial People's Hospital · Tests: Garsorasib, Ivonescimab Combined With Chemotherapy, Surgery, Garsorasib, Ivonescimab Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors NCT06625775Phase 144 sites📍 Duarte📍 Los Angeles📍 San Diego TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics) · Tests: BBO-10203, Trastuzumab, Fulvestrant, Ribociclib, FOLFOX BBO-11818 in Adult Subjects With KRAS Mutant Cancer NCT06917079Phase 117 sites📍 Los Angeles📍 Sacramento📍 San Diego TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics) · Tests: BBO-11818, Pembrolizumab, Platinum chemotherapy (cisplatin or carboplatin), Pemetrexed, Cetuximab
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy